Reverb Therapeutics, a company harnessing the body’s immune system and cytokine signaling to treat life-threatening diseases, has launched a collaboration with Royalmount Laboratories, based in Montreal, as Reverb works towards lead selection and pre-IND enabling work on its first drug candidate.
 
Royalmount Laboratories is one of Canada’s premier CRO organizations, supporting biopharma and pharma companies with their bioanalytical needs to advance their discovery, preclinical and clinical programs.
 
“As we move towards the start of clinical trials in about 18 months’ time, we needed a scientific partner that could assist with toxicity studies, scale-up of manufacturing, and a variety of CMC tasks to ensure that our drug candidate moves swiftly from the lab to the clinic,” said David de Graaf, Ph.D., CEO of Reverb Therapeutics. “We are impressed with Royalmount Laboratories’ capabilities and the quality of their staff.”
 
Adrien Musuku, Senior Director of biopharmaceutics for Royalmount Laboratories, said, “We are proud to support companies like Reverb Therapeutics, an early-stage firm with novel science and a unique approach to harnessing the power of cytokines to treat disease. Reverb Therapeutics is a perfect example of the kind of dynamic company we want to help advance to the clinic and beyond.”
 
Terms of the collaboration were not disclosed. Development work for Reverb begins immediately.